|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Berry DA et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295(14):1658-67. Abstract
Bria E et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer 2006;106(11):2337-44. Abstract
Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;(7):643-51. Abstract
Geyer CE et al. A phase III randomized, open-label, international study comparing lapatinib and capecitabine vs capecitabine in women with refractory advanced metastatic breast cancer (EGF100151). Presentation. Proc ASCO 2006. No abstract available
Joensuu H et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract
Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-time therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 3.
Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract
Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract
Paik S et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:1991-8. Abstract
Paik S et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70. Abstract
Piccart-Gebhart MJ et al. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract
Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2 positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract
 |
 |
